Enteric Soft Capsule for Omega-3 Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Traditional soft gelatin fish oil capsules cause unpleasant side effects such as fishy odor, gastric disturbances, and poor bioavailability due to breakdown in the stomach, and existing enteric coatings face issues like surface roughness, cracking, and loss of clarity, making them unsuitable for omega-3 fatty acid delivery.
Innovation Solution
Development of an enteric soft capsule shell with a matrix fill comprising eicosapentaenoic acid (EPA) that is resistant to gastric acid and dissolves in intestinal fluid, providing enhanced bioavailability and stability, while maintaining the clarity and elasticity of the gelatin capsule.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If traditional soft gelatin capsules are used for fish oil delivery, then the capsule provides ease of ingestion and basic protection, but it causes fishy odors, gastric disturbances, and poor bioavailability due to breakdown in the stomach
Solution Approach 1:
The patent uses an enteric coating layer as an intermediary barrier between the fish oil capsule core and the gastric environment. This coating prevents direct contact between the oil and stomach acid, eliminating fishy odors and gastric disturbances while allowing the capsule to pass through the stomach intact and release contents in the intestine.
Solution Approach 2:
The patent modifies the dissolution parameters of the capsule shell by using enteric-coated gelatin that is resistant to gastric acid (pH 1.2) but dissolves at intestinal pH (≥4.5). This parameter change in pH-dependent solubility allows the capsule to withstand stomach conditions while releasing contents in the intestine, improving bioavailability.
2Reliability
If enteric coating is applied to protect the capsule from gastric acid, then the capsule resistance to stomach acid is improved, but the coating causes surface roughness, cracking, and loss of clarity
Solution Approach 1:
The patent employs a composite enteric coating system combining gelatin with acid-insoluble polymers (such as cellulose acetate phthalate or hydroxypropyl methylcellulose phthalate). This composite structure provides robust gastric acid resistance while the gelatin matrix maintains surface smoothness, elasticity, and optical clarity that pure polymer coatings cannot achieve.
Solution Approach 2:
The patent uses a thin film enteric coating applied to the soft gelatin capsule shell. This thin film approach maintains the flexibility and elasticity of the original gelatin capsule while providing the necessary acid resistance, preventing cracking and flaking that occur with thicker or more rigid coating layers.
3Ease of manufacture
If the capsule shell is made elastic and smooth for ease of manufacture, then the manufacturing process is simplified, but it becomes difficult to form an intact enteric coating without a subcoating step
Solution Approach 1:
The patent merges the enteric coating function directly into the gelatin capsule shell formulation itself, rather than applying it as a separate layer. The enteric-coated gelatin is incorporated into the shell matrix during manufacturing, eliminating the need for separate subcoating steps and simplifying the overall coating process while maintaining ease of manufacture.
4Reliability
If enteric coating is applied to protect contents from stomach acid, then the bioavailability is potentially improved, but the coating causes hazy and opaque appearance and requires additional manufacturing steps
Solution Approach 1:
The patent uses a composite enteric coating system where gelatin (which provides optical clarity) is combined with acid-insoluble polymers (which provide acid resistance). This composite approach maintains the transparent, shiny appearance of gelatin capsules while achieving the necessary enteric protection, avoiding the hazy and opaque appearance caused by pure polymer coatings.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The enteric soft capsule formulation significantly reduces gastrointestinal side effects and enhances the bioavailability of omega-3 fatty acids, achieving stable and controlled release, with improved pharmacokinetic parameters and reduced LDL levels, making it effective for treating cardiovascular-related diseases without unpleasant odors or tastes.
Implementation Method 1
The enteric coating method involves spraying an aqueous or organic solution or suspension of one or more enteric polymers onto tumbling or moving tablets or capsules, followed by drying at elevated temperatures. Enteric dosage forms made by this coating method can suffer from various process-related problems that affect the performance and/or appearance of the coating.
Implementation Method 2
Enteric dosage forms are useful for protecting the contents of the dosage form from the gastric conditions of the stomach and/or to protect gastric tissue from an irritant material contained in the dosage form.
Implementation Method 3
The enteric coating method involves spraying an aqueous or organic solution or suspension of one or more enteric polymers onto tumbling or moving tablets or capsules, followed by drying at elevated temperatures.
Implementation Method 4
The enteric coating method involves spraying an aqueous or organic solution or suspension of one or more enteric polymers onto tumbling or moving tablets or capsules, followed by drying at elevated temperatures.
Data Source
AI summary
Described herein are pharmaceutical compositions providing enhanced bioavailability of polyunsaturated fatty acids and methods of manufacturing the same. In particular, described herein are pharmaceutical compositions comprising soft enteric capsules that provide enhanced bioavailability of omega-3 polyunsaturated fatty acids. The oral pharmaceutical compositions described herein are useful as nutritional supplements or for the treatment of cardiovascular-related diseases, such as hyper dyslipidemia and moderate to high triglyceride levels.